Article Information
History
- July 25, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Hongxing Pan, MSc1,*,
- Qianhui Wu, MPH2,*,
- Gang Zeng, Ph.D.3,*,
- Juan Yang, Ph.D.1,
- Deyu Jiang, MSc4,
- Xiaowei Deng, MSc2,
- Kai Chu, MSc1,
- Wen Zheng, BSc2,
- Fengcai Zhu, M.D.5,†,#,
- Hongjie Yu, M.D. Ph.D.2,6,7,†,# and
- Weidong Yin, MBA8,†,#
- 1Vaccine Evaluation Institute, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
- 2School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
- 3Clinical Research Department, Sinovac Biotech Co., Ltd., Beijing, China
- 4Covid-19 Vaccine Department, Sinovac Life Sciences Co., Ltd., Beijing, China
- 5Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
- 6Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China
- 7Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China
- 8Sinovac Biotech Co., Ltd., Beijing, China
- ↵#Corresponding to
Fengcai Zhu, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210000, China, Email: jszfc{at}vip.sina.com; Hongjie Yu, School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai 200032, China, E-mail: yhj{at}fudan.edu.cn; Weidong Yin, Sinovac Biotech Co., Ltd., Beijing 100085, China, Email: yinwd{at}sinovac.com.
↵* These authors contributed equally.
Posted July 25, 2021.
Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial
